Kobo Biotech Limited (KOBO) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Kobo Biotech Limited ₹9.14, price ₹4.59, upside +99.1%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹1.90 – ₹10.85 · fair‑value band ₹2.81 – ₹17.28 · the ₹4.59 price screens below the ₹9.14 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Kobo Biotech in your weekly email
Every Wednesday you see whether Kobo Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kobo Biotech Limited manufactures active pharmaceutical ingredients based on fermentation technology in India. The company was formerly known as Avon Lifesciences Limited and changed its name to Kobo Biotech Limited in October 2020. Kobo Biotech Limited was incorporated in 1993 and is based in Mumbai, India.
Stock analysis
Kobo Biotech Limited (KOBO) currently trades at ₹4.59, while our model-based Fair Value estimate is ₹9.14, implying the stock looks roughly 49.8% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: ₹2.81 (bear) to ₹17.28 (bull), the price of ₹4.59 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Kobo Biotech Limited reported revenue of ₹0 in FY2025 versus ₹0 in FY2021. Reported net income was −₹52.3M in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 120% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at 99%, KOBO screens cheaper than that median.
Fair Value models
Bear ₹2.81Fair Value ₹9.14Bull ₹17.28
Price ₹4.59 · Upside +99.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +18.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 571 stocks
Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+99.1% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−4.5% · Bottom 25%
Growth and dividend
Revenue growth0.0% · Below median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)1.49× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 16
FUTURE (revenue growth)0· sector 25
PAST (return on equity)0· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 31
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Kobo Biotech Limited (KOBO) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹9.14 versus a price of ₹4.59, about +99% upside (undervalued).
What is the fair value of KOBO?
Our model-based fair value for Kobo Biotech Limited is ₹9.14 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹4.59.
What is the quality score of KOBO?
Kobo Biotech Limited has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kobo Biotech Limited (KOBO)?
Our model-based price target is the fair value of ₹9.14 (as of Sep 27, 2026) from 2 valuation models. Cautious scenario ₹2.81, optimistic scenario ₹17.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Kobo Biotech Limited stock forecast for 2026?
Our models put fair value at ₹9.14, about +99% upside versus a price of ₹4.59 (undervalued). Cautious scenario ₹2.81, optimistic scenario ₹17.28. The calculation is refreshed regularly with new filings.
What is the revenue of Kobo Biotech Limited (KOBO)?
Kobo Biotech Limited reported trailing-twelve-month revenue of about ₹760K (latest available figure, as of Sep 27, 2026).
What growth is priced into Kobo Biotech Limited (KOBO)?
For today's price to be fair in a discounted-cash-flow model, Kobo Biotech Limited would have to grow free cash flow by +23.8 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). As of Sep 27, 2026.
What discount rate (WACC) does the fair value of KOBO use?
Our models discount Kobo Biotech Limited at 10.9 %: a base by market capitalisation (nano), damped by beta 0.46, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kobo Biotech Limited that is +23.8 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How fast is the sector of Kobo Biotech Limited (KOBO) growing?
The median revenue growth in the sector is +5.4 % a year. That is the yardstick for the growth priced into Kobo Biotech Limited (+23.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kobo Biotech Limited (KOBO)?
The free-cash-flow yield on the price is 38.18 %: that much free cash flow Kobo Biotech Limited produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kobo Biotech Limited (KOBO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kobo Biotech Limited it is ₹9.14 per share (as of Sep 27, 2026), against a price of ₹4.59. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Kobo Biotech Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, KOBO trades below its calculated fair value: price ₹4.59, fair value ₹9.14, a gap of about +99% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KOBO?
No. The price is what the market pays today (₹4.59); the fair value is what the company's own numbers justify (₹9.14). For Kobo Biotech Limited the two are ₹4.55 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kobo Biotech Limited worth?
The market values Kobo Biotech Limited at about ₹109M (market capitalisation, as of Sep 27, 2026). Per share that is ₹4.59; our models calculate a fair value of ₹9.14 per share.
What do the bullish and bearish scenarios say about KOBO?
Our models span a range for Kobo Biotech Limited: cautious scenario ₹2.81, base ₹9.14, optimistic ₹17.28 per share (as of Sep 27, 2026, price ₹4.59). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kobo Biotech Limited (KOBO)?
Balance-sheet figures for Kobo Biotech Limited (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is KOBO from its 52-week high?
Kobo Biotech Limited trades at ₹4.59, about 53% below its 52-week high of ₹9.82 and 120% above the low of ₹2.09 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹9.14 is for.
Which stocks are comparable to Kobo Biotech Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kobo Biotech Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹4.59, calculated fair value ₹9.14 (+99%), Quality Score 52/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KOBO calculated?
We run Kobo Biotech Limited through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹9.14, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.6 % above its aggregate fair value. Kobo Biotech Limited currently trades 50 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kobo Biotech Limited (KOBO)?
The closing price on Oct 9, 2026 was ₹4.59. Our model-based fair value is ₹9.14, about +99% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kobo Biotech Limited right now?
The model range is unusually wide (₹2.81 to ₹17.28). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Kobo Biotech Limited
How large is the market capitalisation of Kobo Biotech Limited (KOBO)?
The market capitalisation of Kobo Biotech Limited is ₹109M (≈ $1.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Kobo Biotech Limited (KOBO)?
Earnings per share at Kobo Biotech Limited are ₹−2.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Kobo Biotech Limited (KOBO)?
On an EBIT basis the return on assets of Kobo Biotech Limited is 24.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kobo Biotech Limited (KOBO)?
The operating margin of Kobo Biotech Limited is −6,752% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much net debt does Kobo Biotech Limited (KOBO) carry?
The net debt of Kobo Biotech Limited is ₹1.4B (fiscal year 2025, ≈ 33.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kobo Biotech Limited in the live analysis
One click puts Kobo Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
